2025³â 04¿ù 04ÀÏ ±Ý¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

´º½ºÀÏÀÚ: 2022-06-08

FORT WORTH, TEXAS-- June 08, 2022 -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will present four scientific presentations at the 2022 Vegas Cosmetic Surgery (VCS) & Aesthetic Dermatology Annual Symposium to showcase the latest advancements surrounding its approved and investigational product updates.

“We look forward to unveiling the latest data and research across our innovative dermatology pipeline and portfolio at this year’s VCS symposium,” said Bill Andriopoulos, Vice President, Medical Affairs Galderma U.S. “Our commitment to patients is underscored by the dermatological solutions we are investigating and bringing to market. We are excited to continue to realize the potential of our product portfolio and share our findings with the larger scientific community.”

The data presentations stem from Galderma’s neuromodulators relabotulinumtoxinA (QM1114), an investigational product, and Dysport® (abobotulinumtoxinA)* as well as its collagen stimulator, Sculptra® (injectable poly-L-lactic acid).

There will be two scientific presentations featuring the latest READY-1 and READY-2 Phase 3 data of relabotulinumtoxinA, a proprietary novel, ready-to-use, liquid formulation of investigational botulinum toxin, for the treatment of glabellar lines and lateral canthal lines. There will also be data presented from across three individual trials investigating the subject-relevant outcomes of on-label 50U Dysport for the treatment for moderate-to-severe glabellar lines. Additionally, data from NCT03780244, an open-label extension study to evaluate the safety and effectiveness of Sculptra after changes in reconstitution and injection procedure, will be presented at the symposium.



 Àüü´º½º¸ñ·ÏÀ¸·Î

DDC Announces Strategy to Create Bitcoin Reserves and Appoints Crypto Asset Expert Alex Yang as Strategic Advisor
Venture Global Receives Non-FTA Export Authorization for CP2 LNG
DEWA¡¯s General Assembly Approves Dividend Payment of AED 3.1 Billion to Shareholders for H2 of 2024
Klick Health Acquires Ward6 Singapore
Andersen Global Broadens Reach in Bangladesh with Edge Research
Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales
Iochpe-Maxion Names Pieter Klinkers President and CEO

 

Japan¡¯s Cross-border E-Commerce ¡°WAFUU.COM¡± Adds Shipping to 37 New...
Laserfiche Announces 2025 Run Smarter¢ç Award Winners
Energy Vault Acquires 1.0 GWh Stoney Creek BESS from Enervest, Advanci...
Xsolla Releases Q1 2025 Report on the Future of Global Gaming and Game...
Andersen Global Broadens Canadian Platform with MMCA & Associates LLP
NetApp Prices $1.25 Billion of Senior Notes
ATLAS Welcomes Strengthened Commitment to Increased Shareholder Return...

 


°øÁö»çÇ×
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øü Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..